A trial led by the Duke Clinical Research Institute in North Carolina and other health facilities such as the Medical University of South Carolina (MUSC) began a new clinical trial open for everyone 30 years or older. The trial will determine if the other three drugs are efficient and safe to treat the SARS-CoV-2 infection and symptoms. Those who want to participate in the trial can choose which study arm they want. The three drugs that are currently being studied are ivermectin, fluticasone, and fluvoxamine.
What you need to know about the ACTIV-6 trial:
Doctor Leslie Lenert, director of the Biomedical Informatics Center at MUSC, explains that anyone interested can participate in the remote trial. Most of the time, patients participating in a health trial would have to live close to a health facility that collaborates with the researchers. However, this clinical trial will be remote, meaning that those who want to participate will not have to go to a doctor’s office.
Who qualifies for the study?
Those who want to participate in the study need to be 30 years old or older, and they can participate from anywhere in the U.S. Patients must have tested positive for Covid-19 in the past ten days and should have experienced at least two symptoms related to the infection for seven days or less. The ACTIV-6 clinical trial will use three drugs, and they will be shipped to patient’s homes. Each patient can choose which drug they would like to use.
More information on the three drugs
The official page of the trial contains information on the three drugs. Fluticasone is an inhaled steroid, and it is a prophylactic treatment for asthma and other lung-related diseases. Ivermectin is a drug used for parasitic infections in animals. Fluvoxamine is a selective serotonin reuptake inhibitor, and it is usually prescribed to those who suffer from depression.
Those accepted in the trial will have to take the drug as prescribed and fill in several surveys. Each participant will receive a $100 Amazon gift card after 90 days of treatment.